BCL2 and neoplasm: Thus, immunohistochemistry (IHC) investigation demonstrated that ECPU-0001 treatment clearly reduced expression of BCL-2 and BCL-2-xL, while enhanced expression of BAX (Figure 7F and Figure S7) in tumor.